Axxam Provides Screening Assays to NIH Chemical Genomics Centre
News Jan 10, 2006
Axxam has announced that it has signed an agreement with the National Institutes of Health ( NIH) to provide access to a selection of screening assays of special interest to the NIH Chemical Genomics Centre ( NCGC) for use in the screening campaigns within the Molecular Libraries Roadmap Initiative.
The screening assays were developed and optimized at Axxam for ultra high-throughput screening (uHTS) applications using ultra sensitive signal detection methods.
"We are very pleased to collaborate with the NIH Chemical Genomics Centre in support of their screening efforts," stated Dr. Lia Scarabottolo, head of cell biology at Axxam.
"We believe that our expertise in the uHTS sector, with a particular emphasis on cell-based assays and their use in large screening campaigns, could provide an important contribution to the future success of the Roadmap initiative at the NCGC."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.